Gumerlock PH - Search Results

1

Functional p53 increases prostate cancer cell survival after exposure to fractionated doses of ionizing radiation.

Scott SL, Earle JD, Gumerlock PH. Scott SL, et al. Among authors: gumerlock ph. Cancer Res. 2003 Nov 1;63(21):7190-6. Cancer Res. 2003. PMID: 14612513

2

Survival and cell cycle kinetics of human prostate cancer cell lines after single- and multifraction exposures to ionizing radiation.

Scott SL, Gumerlock PH, Beckett L, Li Y, Goldberg Z. Scott SL, et al. Among authors: gumerlock ph. Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):219-27. doi: 10.1016/j.ijrobp.2004.01.027. Int J Radiat Oncol Biol Phys. 2004. PMID: 15093919

3

BCL2 antisense reduces prostate cancer cell survival following irradiation.

Scott SL, Higdon R, Beckett L, Shi XB, deVere White RW, Earle JD, Gumerlock PH. Scott SL, et al. Among authors: gumerlock ph. Cancer Biother Radiopharm. 2002 Dec;17(6):647-56. doi: 10.1089/108497802320970253. Cancer Biother Radiopharm. 2002. PMID: 12537668

4

Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors.

Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, deVere White RW. Meyers FJ, et al. Among authors: gumerlock ph. Cancer. 1998 Dec 15;83(12):2534-9. Cancer. 1998. PMID: 9874460

5

Critical Lym-1 binding residues on polymorphic HLA-DR molecules.

Rose LM, Deng CT, Scott SL, Xiong CY, Lamborn KR, Gumerlock PH, DeNardo GL, Meares CF. Rose LM, et al. Among authors: gumerlock ph. Mol Immunol. 1999 Aug;36(11-12):789-97. doi: 10.1016/s0161-5890(99)00083-8. Mol Immunol. 1999. PMID: 10593517 No abstract available.

6

Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells.

Mack PC, Jones AA, Gustafsson MH, Gandara DR, Gumerlock PH, Goldberg Z. Mack PC, et al. Among authors: gumerlock ph. Radiat Res. 2004 Dec;162(6):623-34. doi: 10.1667/rr3253. Radiat Res. 2004. PMID: 15548112

7

Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells.

Devlin HL, Mack PC, Burich RA, Gumerlock PH, Kung HJ, Mudryj M, deVere White RW. Devlin HL, et al. Among authors: gumerlock ph. Mol Cancer Res. 2008 May;6(5):808-18. doi: 10.1158/1541-7786.MCR-07-2027. Mol Cancer Res. 2008. PMID: 18505925 Free article.

8

RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma.

Mack PC, Gandara DR, Bowen C, Edelman MJ, Paglieroni T, Schnier JB, Gelmann EP, Gumerlock PH. Mack PC, et al. Among authors: gumerlock ph. Clin Cancer Res. 1999 Sep;5(9):2596-604. Clin Cancer Res. 1999. PMID: 10499638

9

Application of a yeast assay to detect functional p53 mutations in archival prostate cancer tissue.

Shi XB, Di Mauro SM, Highshaw R, Deitch AD, Evans CP, Gumerlock PH, deVere White RW. Shi XB, et al. Among authors: gumerlock ph. Cancer Biother Radiopharm. 2002 Dec;17(6):657-64. doi: 10.1089/108497802320970262. Cancer Biother Radiopharm. 2002. PMID: 12537669

10

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.

Lara PN Jr, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR. Lara PN Jr, et al. Among authors: gumerlock ph. Cancer. 2004 May 15;100(10):2125-31. doi: 10.1002/cncr.20228. Cancer. 2004. PMID: 15139054 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters